Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $301.86 | 10 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $127.17 | 2 | $0 (2024) |
| ViiV Healthcare Company | $73.51 | 3 | $0 (2024) |
| ABBVIE INC. | $71.73 | 3 | $0 (2024) |
| Janssen Biotech, Inc. | $14.85 | 1 | $0 (2019) |
| Gilead Sciences, Inc. | $14.60 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $142.56 | 6 | ViiV Healthcare Company ($73.51) |
| 2019 | $51.76 | 3 | AbbVie, Inc. ($36.91) |
| 2017 | $107.54 | 1 | Merck Sharp & Dohme Corporation ($107.54) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/27/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $14.60 | General |
| Category: COVID-19 | ||||||
| 11/25/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $20.95 | General |
| Category: HIV | ||||||
| 09/26/2024 | Merck Sharp & Dohme LLC | PIFELTRO (Drug), DELSTRIGO | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 09/24/2024 | ViiV Healthcare Company | — | Food and Beverage | In-kind items and services | $29.26 | General |
| 09/03/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $34.82 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/24/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $23.30 | General |
| Category: HIV | ||||||
| 09/12/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $18.91 | General |
| Category: Virology | ||||||
| 08/07/2019 | Janssen Biotech, Inc. | Symtuza (Drug), Juluca | Food and Beverage | In-kind items and services | $14.85 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 07/23/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Virology | ||||||
| 05/22/2017 | Merck Sharp & Dohme Corporation | ISENTRESS (Drug) | Food and Beverage | In-kind items and services | $107.54 | General |
| Category: INFECTIOUS DISEASE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 41 | 50 | $12,814 | $3,829 |
| 2022 | 3 | 57 | 62 | $16,020 | $4,931 |
| 2021 | 1 | 48 | 63 | $17,766 | $3,764 |
| 2020 | 9 | 537 | 744 | $197,029 | $53,098 |
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 22 | $7,634 | $2,140 | 28.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 28 | $5,180 | $1,689 | 32.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 28 | 28 | $8,792 | $2,677 | 30.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 22 | $5,236 | $1,672 | 31.9% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 12 | $1,992 | $581.85 | 29.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 48 | 63 | $17,766 | $3,764 | 21.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 101 | 208 | $58,036 | $16,062 | 27.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 113 | 120 | $31,560 | $11,982 | 38.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 129 | 178 | $45,267 | $9,784 | 21.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 85 | 127 | $26,797 | $6,369 | 23.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 35 | 37 | $15,466 | $3,132 | 20.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 20 | 20 | $6,724 | $2,985 | 44.4% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Office | 2020 | 28 | 28 | $11,469 | $2,320 | 20.2% |
| 90686 | Vaccine for influenza for administration into muscle, 0.5 ml dosage | Office | 2020 | 13 | 13 | $653.00 | $254.54 | 39.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2020 | 13 | 13 | $1,057 | $209.43 | 19.8% |
About Dr. Rohit Kalia, MD
Dr. Rohit Kalia, MD is a Infectious Disease healthcare provider based in Newport News, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/03/2010. The National Provider Identifier (NPI) number assigned to this provider is 1417277112.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rohit Kalia, MD has received a total of $301.86 in payments from pharmaceutical and medical device companies, with $142.56 received in 2024. These payments were reported across 10 transactions from 5 companies. The most common payment nature is "Food and Beverage" ($301.86).
As a Medicare-enrolled provider, Kalia has provided services to 683 Medicare beneficiaries, totaling 919 services with total Medicare billing of $65,621. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Other Specialties Infectious Disease, Internal Medicine
- Location Newport News, VA
- Active Since 06/03/2010
- Last Updated 10/03/2024
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1417277112
Products in Payments
- ISENTRESS (Drug) $107.54
- Mavyret (Drug) $36.91
- DALVANCE (Drug) $34.82
- DOVATO (Drug) $23.30
- CABENUVA (Biological) $20.95
- PIFELTRO (Drug) $19.63
- Symtuza (Drug) $14.85
- Veklury (Drug) $14.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Newport News
Andrea Gonzalez, M.d, M.D
Infectious Disease — Payments: $19,320
Jeffrey Harris, M.d, M.D
Infectious Disease — Payments: $1,136
Dr. Martha Mooney, Md, MD
Infectious Disease — Payments: $768.23
Dr. Prakash Kafle, M.d, M.D
Infectious Disease — Payments: $274.09
Dr. Sharon Hopson, M.d, M.D
Infectious Disease — Payments: $108.19